tradingkey.logo


tradingkey.logo


Bausch Health Companies Inc

BHC
5.020USD
-0.100-1.95%
āļ›āļīāļ” 03/27, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
1.53BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
11.86P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Bausch Health Companies Inc āļšāļĢāļīāļĐāļąāļ—

Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.

āļ‚āđ‰āļ­āļĄāļđāļĨ Bausch Health Companies Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™BHC
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Bausch Health Companies Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 20, 1994
āļ‹āļĩāļ­āļĩāđ‚āļ­Appio (Thomas J)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™20700
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Sep 20
āļ—āļĩāđˆāļ­āļĒāļđāđˆ2150 St. Elzear Blvd. West
āđ€āļĄāļ·āļ­āļ‡LAVAL
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX NASDAQ Basic NYSE
āļ›āļĢāļ°āđ€āļ—āļĻCanada
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒH7L 4A8
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ18003611448
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.bauschhealth.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™BHC
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 20, 1994
āļ‹āļĩāļ­āļĩāđ‚āļ­Appio (Thomas J)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Bausch Health Companies Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
1.25M
-97.78%
Mr. Jean-Jacques (JJ) Charhon
Mr. Jean-Jacques (JJ) Charhon
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
440.81K
+54.80%
Ms. Aimee J. Lenar
Ms. Aimee J. Lenar
Executive Vice President, US Pharma
Executive Vice President, US Pharma
164.94K
+84.61%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
108.65K
+0.91%
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
8.26K
+55.53%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
6.60K
-3758.85%
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Richard C. Mulligan, Ph.D.
Dr. Richard C. Mulligan, Ph.D.
Independent Director
Independent Director
--
--
Ms. Seana Carson
Ms. Seana Carson
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
1.25M
-97.78%
Mr. Jean-Jacques (JJ) Charhon
Mr. Jean-Jacques (JJ) Charhon
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
440.81K
+54.80%
Ms. Aimee J. Lenar
Ms. Aimee J. Lenar
Executive Vice President, US Pharma
Executive Vice President, US Pharma
164.94K
+84.61%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
108.65K
+0.91%
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
8.26K
+55.53%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
6.60K
-3758.85%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Pharmaceutical Products
4.40B
45.67%
Device Products
2.24B
23.27%
OTC
1.90B
19.77%
Branded and Other Generic Products
979.00M
10.17%
Other Product Lines
107.00M
1.11%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States and Puerto Rico
5.77B
59.92%
Other Foreign Countries
1.08B
11.25%
China (Country)
496.00M
5.15%
Canada
402.00M
4.18%
Poland
350.00M
3.64%
āļ­āļ·āđˆāļ™ āđ†
1.53B
15.86%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Pharmaceutical Products
4.40B
45.67%
Device Products
2.24B
23.27%
OTC
1.90B
19.77%
Branded and Other Generic Products
979.00M
10.17%
Other Product Lines
107.00M
1.11%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 21 āļĄāļĩ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 21 āļĄāļĩ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Paulson & Co. Inc.
19.77%
Meruelo (Alex)
9.92%
GoldenTree Asset Management, LP
9.35%
The Vanguard Group, Inc.
2.86%
Nomura Securities Co., Ltd.
2.35%
āļ­āļ·āđˆāļ™ āđ†
55.74%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Paulson & Co. Inc.
19.77%
Meruelo (Alex)
9.92%
GoldenTree Asset Management, LP
9.35%
The Vanguard Group, Inc.
2.86%
Nomura Securities Co., Ltd.
2.35%
āļ­āļ·āđˆāļ™ āđ†
55.74%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Family Office
19.79%
Investment Advisor/Hedge Fund
16.53%
Individual Investor
11.19%
Holding Company
9.37%
Investment Advisor
8.26%
Hedge Fund
6.92%
Research Firm
5.61%
Bank and Trust
3.84%
Pension Fund
2.86%
āļ­āļ·āđˆāļ™ āđ†
15.63%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
488
175.10M
70.29%
+43.88K
2025Q3
506
175.09M
71.73%
-42.59M
2025Q2
513
217.71M
72.26%
-4.52M
2025Q1
526
222.33M
72.55%
-45.74M
2024Q4
547
234.63M
78.06%
-1.57M
2024Q3
606
235.66M
83.60%
-25.41M
2024Q2
682
261.12M
90.70%
-4.43M
2024Q1
745
265.27M
94.42%
-80.93M
2023Q4
778
267.72M
94.93%
+4.99M
2023Q3
794
262.66M
89.53%
+17.36M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Paulson & Co. Inc.
73.26M
19.75%
+2.50M
+3.53%
Nov 25, 2025
Meruelo (Alex)
36.76M
9.91%
+148.73K
+0.41%
Mar 31, 2025
GoldenTree Asset Management, LP
34.83M
9.39%
+578.54K
+1.69%
Sep 30, 2025
The Vanguard Group, Inc.
12.17M
3.28%
+470.97K
+4.02%
Sep 30, 2025
Nomura Securities Co., Ltd.
15.71M
4.24%
-5.79M
-26.92%
Sep 30, 2025
Healthcare Of Ontario Pension Plan
13.00M
3.51%
--
--
Sep 30, 2025
MFN Partners Management LP
6.00M
1.62%
--
--
Sep 30, 2025
National Bank of Canada
7.72M
2.08%
-16.55K
-0.21%
Sep 30, 2025
Kohlberg Kravis Roberts & Co. L.P.
5.24M
1.41%
--
--
Sep 30, 2025
RBC Brewin Dolphin
5.20M
1.4%
--
--
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
VanEck Pharmaceutical ETF
0.3%
Gotham 1000 Value ETF
0.18%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
0.12%
Schwab International Small-Cap Equity ETF
0.09%
iShares Intl Small Cap Equity Factor ETF
0.08%
DFA Dimensional International Small Cap ETF
0.07%
Schwab Fundamental International Equity ETF
0.04%
Invesco RAFI Developed Mkts ex-US ETF
0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
0.01%
iShares Core MSCI International Developed Mkt ETF
0.01%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
VanEck Pharmaceutical ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.3%
Gotham 1000 Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.18%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.12%
Schwab International Small-Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.09%
iShares Intl Small Cap Equity Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.08%
DFA Dimensional International Small Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.07%
Schwab Fundamental International Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.04%
Invesco RAFI Developed Mkts ex-US ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
iShares Core MSCI International Developed Mkt ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™